GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note Monday.

The analysts said they have a positive outlook on the company as GE HealthCare Technologies offers an attractive risk-reward profile, with its valuation not fully reflecting its growth potential.

Following its 2023 separation from General Electric, the company has increased research and development investment and improved commercial execution, helping to drive 5% year-over-year order growth in 2025.

The company also has a strong $22 billion backlog, roughly equivalent to its expected 2026 revenue, positioning it for faster growth later in the year toward its long-range plan.

Management is targeting annual organic revenue growth of 4% to 6% between 2026 and 2028, along with high-single-digit to low-double-digit earnings-per-share growth, the analysts said.

For sales, GE HealthCare is expected to deliver organic revenue growth within its 3% to 4% guidance range in 2026, the analysts said, adding that they expect 2027 EPS of $5.45, slightly above the consensus estimate of $5.40.

RBC initiated coverage of GE HealthCare Technologies with an outperform rating and an $80 price target.

Price: 62.47, Change: +1.83, Percent Change: +3.02